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A novel resistance-linked ovine PrP variant and its equivalent mouse variant 
modulate the in vitro cell-free conversion of rPrP to PrP
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Summary 
Prion diseases are associated with the conversion of the normal cellular 
prion protein, PrPc, to the abnormal disease associated PrPSc. This conversion 
can be mimicked in vitro using the cell-free conversion assay. We have 
recently shown that this assay can be modified to use bacterial recombinant 
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PrP as substrate and mimic the in vivo transmission characteristics of rodent 
scrapie. Here we demonstrate that the assay replicates the ovine 
polymorphism barriers of scrapie transmission. In addition, the recently 
identified ovine PrP variant ARL
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168Q, which is associated with survival of 
sheep to experimental BSE, modulates the cell-free conversion of ovine 
recombinant PrP to PrPres by 3 different types of PrPSc, reducing conversion 
efficiencies to levels similar to the ovine resistance-associated ARR variant. 
Also, the equivalent variant in mice (L164) is resistant to conversion by 87V 
scrapie. Together these results suggest a significant role for this position 
and/or amino acid in conversion. 
 
Transmissible spongiform encephalopathies (TSEs) are fatal 
neurodegenerative diseases including Creutzfeldt-Jakob disease in humans, scrapie 
in sheep and goats and bovine spongiform encephalopathy (BSE) in cattle. The 
causative agent responsible for TSEs or prion diseases has yet to be fully defined. 
However, a fundamental event in disease is the conversion of the normal, proteinase 
K (PK) sensitive isoform of the prion protein, PrPc, to an abnormal, partially PK 
resistant isoform, PrPSc, and the accumulation of this abnormal isoform in the central 
nervous system of infected animals (Hope et al., 1986; Meyer et al., 1986; Oesch et 
al., 1985). Although the mechanism of conversion is unknown, interaction between 
PrPc and PrPSc is critically implicated by in vitro studies (Caughey & Chesebro, 1997) 
and features in the current models of replication (Prusiner, 1991; Jarrett & Lansbury, 
1993). 
Polymorphisms in PrP are associated with susceptibility to and pathology of 
TSEs. The major determinants controlling the susceptibility of sheep to scrapie are 
 2
polymorphisms at PrP amino acid codons 136, 154 and 171 (Hunter et al., 1997). 
The PrP ARR allele (amino acids, in single letter code, at positions 136, 154 and 171 
respectively) is associated with resistance to classical scrapie. The PrP ARQ and 
VRQ alleles are associated with susceptibility to disease. Novel ovine PrP 
polymorphisms are regularly being identified in sheep genotyping programs. Most of 
these novel polymorphisms occur with low frequency and their association with 
disease susceptibility is not known (Baylis & Goldmann, 2004). It is important to 
assess the disease association of such variants in the hope of identifying additional 
scrapie resistant alleles, as not all breeds or populations have significant frequencies 
of the known resistant ARR allele and it has been reported that sheep homozygous 
for the ARR allele may be susceptible to atypical scrapie (Bushmann et al., 2004) 
and intracerebral (ic) inoculation with BSE (Houston et al., 2003). The identification 
of other resistant alleles may also help to protect against novel strains of scrapie or 
adaptation to a particular genotype.  
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Due to the long incubation time and high cost of animal experiments, the in 
vitro cell-free conversion assay has provided a quick, well defined system in which to 
assess the disease association of such alleles (Kocisko et al., 1994). However, for 
natural infection, dose, route, strain of agent, influence of second allele and breed of 
sheep are all likely to play a role in TSE susceptibility and additional evidence from 
experimental challenge would be required to support any association of particular 
alleles with resistance to TSEs. In the cell-free conversion assay PrPSc, isolated from 
the brains of scrapie infected animals, induces the conversion of radiolabelled 
recombinant PrP, to a PK resistant isoform, PrPres (Kocisko et al., 1994). The assay 
has been shown to replicate in vivo species specificity, strain properties and 
polymorphism barriers (Bessen et al., 1995; Bossers et al., 1997; Bossers et al., 
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2000; Iniguez et al., 2000; Kocisko et al., 1995; Zhang et al., 2002; Raymond et al., 
1997; Horiuchi et al., 2000) and has been used to study many aspects of molecular 
conversion. As yet, however, no in vitro cell-free generated PrP
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res has been shown to 
be infectious (Hill et al., 1999). Recently, we reported the use, as substrate, of 
mouse and hamster PrP, biochemically purified from recombinant bacteria and 
demonstrated that the assay replicated several characteristics of in vivo disease 
(Kirby et al., 2003).  
Evidence is presented here that bacterial recombinant ovine PrP can be 
converted to PrPres in the cell-free conversion assay and the sheep polymorphism 
barriers of scrapie transmission are replicated. Full length ovine PrP of the ARR, 
ARQ and VRQ genotypes, with the N-terminal signal sequence replaced with 
methionine and the C-terminal signal sequence removed, corresponding to amino 
acids 25-233, were PCR amplified from genomic DNA using the 5’ and 3’ primers, 5’-
GGATCCATCATGAAGAAGCGACCAAAACCTGGC-3’ and 5’-
CCGAATTCTCATGCCCCCCTTTGGTAATAA-3’, respectively. Plasmid pTrcHIS B  
(Invitrogen) was digested with restriction enzymes NcoI and EcoRI to remove the 6-
histidine tag. PCR fragments were digested with restriction enzymes EcoRI and RcaI 
and ligated into the modified pTrcHis B plasmid. Therefore, the vector encodes full-
length, untagged ovine PrP. Calcium chloride competent Escherichia coli, strain 
1B392 (Wright et al., 1986), were transformed with the recombinant vectors. Ovine 
PrP variants were expressed, radiolabelled, purified, refolded and characterized by 
mass spectrometry and circular dichroism, as described in Kirby et al., (2003). A 
representative autoradiograph is shown in Figure 1, lanes 1-3. PrPSc was purified 
from the brain stems of VRQ homozygous sheep clinically infected with scrapie 
(SSBP/1 source), from ARQ homozygous sheep clinically infected with BSE and 
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from BSE infected cows, based on a method described by Hope et al., (1986). Cell-
free conversion assays were carried out using the 3 radiolabelled ovine PrP variants 
(
101 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 
112 
113 
114 
115 
116 
117 
118 
119 
120 
121 
122 
123 
124 
125 
35 35 35S-rARRPrP, S-rARQPrP, and S-rVRQPrP) as substrates and the 3 different 
PrPSc types as seeds, as described previously (Kirby et al., 2003). Briefly, 1 μg of 
PrPSc 35 was incubated with 200 ng of S-rPrP for 24 hours at 37°C, in a non-
guanidine containing conversion buffer. Following incubation, 1/20th of the reaction 
was treated with 60 μg PK ml-1 for 1 hour at 37°C. PK digestion was stopped by 
adding Pefabloc to 1 mM. All samples were methanol precipitated and analysied by 
SDS-PAGE and autoradiography. Autoradiographs were quantifed using Phoretix 
Gel Analysis Software. A typical autoradiograph is shown in Figure 1A. The 
experiment was repeated 3 times, efficiencies of conversion determined by 
densiometric analysis and the mean conversion efficiencies calculated (±SE) by 
densiometric analysis of labeled PrP before and after PK treatment (Figure 1B). 
Figure 1A shows that bacterial recombinant ovine PrP is converted into a PK 
resistant form in the cell-free conversion assay. The conversion efficiencies obtained 
using bacterial recombinant ovine PrP were low (Figure 1B) in comparison to the 
efficiencies obtained using bacterial recombinant rodent PrP (Kirby et al., 2003). 
Conversion efficiency may be increased by the addition of guanidine to the 
conversion buffer (Bossers et al., 1997). Indeed, it has recently been reported that 
the addition of guanidine to the assay buffer is essential to obtain any conversion of 
sheep PrP (Piening et al., 2006). However, this reduces the physiological relevance 
of the assay as a model of conversion. In addition, the conversion efficiencies 
between sets of experiments (a set is defined as the 5 types of 35S-rOvPrP and 1 
type of PrPSc) varied enormously (Figure 1B). This has been reported by others 
using a similar cell-free conversion assay (Bossers et al., 1997). The reason for this 
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is unknown, but breed of sheep or the area of brain selected for purification of PrPSc 
may contribute.  However, the relative conversion efficiencies within a set were 
similar each time the experiment was repeated. Of the 3 frequently occurring ovine 
PrP variants, ARR, ARQ and VRQ, 
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35S-rARRPrP, the variant associated with 
resistance to classical scrapie, consistently produced the lowest amount of PrPres 
when used as substrate in the cell-free conversion reaction (Figure 1A, lanes 6, 11 
and 16). 35S-rARQPrP 35and S-rVRQPrP, variants associated with susceptibility to 
scrapie and short incubation times, converted with higher efficiencies (Figure 1A, 
lanes 7, 8, 12, 13, 17 and 18). A switch in the convertibility of 35S-rARQPrP 35and S-
rVRQPrP Scis evident with homologous and heterologous PrP . The homologous 
conversion reactions produced the greatest amount of PrPres (Figure 1A, lanes 8 and 
17). These results indicate that the known in vivo polymorphism barriers of scrapie 
transmission can be mimicked in the cell-free conversion assay, using bacterial 
recombinant ovine PrP.  
Recently, Goldmann et al., (2005) have identified two novel ovine PrP alleles. 
Sheep carrying a PrP variant with a proline to leucine polymorphism at amino acid 
168 (L168) were shown to have increased survival time to experimental BSE in 2 
independent experiments (Goldmann, **this reference refers to Wilfred Goldmann’s 
paper to be published alongside my paper). ARL168Q occurs at low frequency and 
although it may be linked with resistance to experimental BSE no data exists on its 
resistance to scrapie infection. The other variant ARQE175, with a change from a 
glutamine to a glutamic acid at amino acid position 175 (E175) is also rare and not yet 
associated with scrapie or BSE susceptibility. Therefore, the cell-free conversion 
assay was used to predict whether these ovine variants are associated with 
resistance to scrapie infection. The 168 and 175 amino acid positions are of interest 
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as they are located close to the putative factor-X binding site (Telling et al., 1995; 
Kaneko et al., 1997) and the resistance-associated R
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171 position. 
In a further experiment 35 168 35S-rARL QPrP and S-rARQE175PrP were 
produced (Figure 1A, lanes 4 and 5), as described above for the other ovine 
variants, and used as substrate in the cell-free conversion assay incubating with the 
3 different PrPSc types. 35S-rARL168QPrP converted with low efficiency using all 3 
types of PrPSc (Figure 1A, lanes 9, 14 and 19), indicating that the ARL168Q effect on 
conversion is significant for scrapie as well as BSE. 35S-rARQE175PrP converted with 
an efficiency similar to 35S-rARQPrP with the 3 different types of PrPSc (Figure 1A, 
lanes 10, 15 and 20), suggesting that this amino acid change does not affect 
conversion. Table 1 provides a rank order of conversion efficiences of the 35S-
rOvPrP variants with the 3 different PrPSc types.  
Due to the low conversion efficiencies and to strengthen the data showing the 
reduced conversion efficiency effect of the ovine ARL168QPrP variant, it was 
determined whether the equivalent site in mouse PrP would have the same effect 
and reduce conversion efficiency. The mouse cell-free conversion assay gives 
higher conversion efficiencies and therefore the effect on conversion can be more 
easily seen. Also, polymorphisms associated with resistance to TSEs in both sheep 
(R171) and humans (K219 167) have been engineered on a mouse background (R  and 
K218, respectively) and the recombinant versions shown not to convert when 
expressed in ScN2a cells (Kaneko et al., 1997), suggesting that mouse PrP can be 
used to model the effects of PrP polymorphisms in other species.  
The murine equivalent of ovine amino acid 168 is 164. Full length mouse PrP 
(amino acids 23-230) of the Prn-pa genotype with a proline to leucine mutation at 
amino acid 164 was constructed by site directed mutatgenesis (QuickChange II, 
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Stratagene) using the full length mouse PrP clone, the production of which has been 
described previously (Kirby et al., 2003), as a template and the following primers; 5’-
CCAAGTGTACTACAGGCTAGTGGATCAGTACAGC-3’ and 5’-
GCTGTACTGATCCACTAGCCTGTAGTACACTTGG-3’. Rosetta Escherichia coli 
(Novagen), which over expresses the rare leucine tRNA, were transformed with 
pTrcMoL
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164PrP. MoL164PrP and MoPrP were expressed, radiolabelled, purified and 
characterized as described for the ovine variants. PrPSc was purified from the brains 
of terminally ill 87V-infected VM mice, based on a method described by Hope et al., 
(1986). Cell-free conversion assays, using the 2 mouse PrP variants as substrates 
and 87V PrPSc as seed, were carried out in the absence of guanidine and analysed 
as described previously (Kirby et al., 2003). The experiment was repeated at least 3 
times and a typical autoradiograph is shown in Figure 2. 
35 resFigure 2 shows that S-rMoPrP is efficiently converted to PrP  in the 
presence of 87V PrPSc 35 (Figure 2, lane 2). However, S-rMoL164 PrP is not converted 
to PrPres Sc in the presence of 87V PrP  (Figure 2, lane 3), suggesting that this amino 
acid/position may be a significant site in the conversion process in other species.   
It is not understood how substitution of different amino acids at certain 
positions within PrP has such a profound effect on susceptibility. It has been 
suggested that mutations can modulate the stability of PrPc Sc, PrP , or both, or can 
affect the binding of PrP to effector molecules. In the case of a proline to leucine 
mutation, the amino acids share similar hydrophobicity, but are structurally diverse. 
Proline, the only imino acid, has backbone torsion angles that are tightly controlled 
as a result of its cyclic structure. Because of this, it results in turns in protein 
backbones and often occurs at the end of β-sheets. A change from proline to 
leucine, which has a greater range of flexibility in its backbone angles, may reduce 
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the propensity of PrP to form β-sheets, and explain the significant protective effect of 
this mutation. Alternatively, leucine is an amino acid capable of involvement in many 
types of secondary structure, including α-helices, and a change to a leucine may aid 
the stabilisation of PrP
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c. Interestingly, the same mutation, proline to leucine, is 
associated with apparent spontaneous disease in humans when it occurs at position 
102 in human PrP, the reverse of what we find for ovine position 168 and its 
equivalent mouse position. This is almost undoubtedly a reflection of the very 
different tertiary structures in the different parts of the molecule and the different 
involvement of these areas in conversion of PrPc to PrPSc. In addition, extensive 
gene-targeted transgenic mouse experiments show that L101 mice have altered 
susceptibility to a range of TSE isolates compared to wildtype mice (Barron et al., 
2001), further complicating interpretation. The neutral phenotype of the ovine PrP 
E175 polymorphism in our assay suggests that not every change in this region of PrP 
will affect susceptibility and indicates that the underlying mechanism may be highly 
positional and residue specific. 
To determine the molecular mechanisms responsible for the protective effect 
of the L168 mutation, substitution of a range of different amino acids at position 168 
would be required and their affect on conversion assessed. Such experiments are 
currently underway in our laboratory using the murine cell-free conversion assay as 
a model. In addition, the ovine and murine version of the cell-free conversion assay 
using bacterial recombinant PrP can be used to assess the link between novel ovine 
polymorphisms, as they are identified, to classical scrapie, atypical scrapie, such as 
NOR98, and to BSE.  
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164 PrP. 
 
Figure 1 legend: 
A) An autoradiograph of a cell-free conversion reaction using 5 ovine recombinant 
variants (35 ScS-rOvPrP) as substrate and PrP , isolated from scrapie infected 
VRQ/VRQ homozygous sheep brains (lanes 6-10), BSE infected cow brains (lanes 
11-15) and BSE infected ARQ/ARQ homozygous sheep brains (lanes 16-20) as 
seeds.  Lanes 6-20 have been exposed for a longer time interval than lanes 1-5 in 
order to detect PrPres. Molecular mass markers are indicated on the left in kDa. (PK) 
proteinase K. Boxed area indicates PrPres. B) Average conversion efficiencies (±SE) 
for each set of conversion reactions (5 types of 35S-rOvPrP and 1 type of PrPSc). 
 
Table 1 legend: 
A summary table of sheep conversion assay data. Each set of conversions (5 35S-
rOvPrP variants converted by 1 type of PrPSc) are ranked in order of decreasing 
conversion efficiency, predicting the susceptibility of the ovine variants to scrapie and 
BSE. 
 
Figure 2 legend: 
An autoradiograph of a cell-free conversion reaction using mouse PrP with and 
without a proline to leucine mutation at amino acid position 164 (equivalent to ovine 
position 168) as substrates and 87V PrPSc as seed. Molecular mass markers are 
indicated on the left in kDa. (PK) proteinase K. Boxed area indicates PrPres. 
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Conversion efficiency of 35S-rOvPrP 
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         VRQ ARQE175 168ARQ ARR ARL Q 
           
Bovine/BSE 
 
ARQE175 VRQ ARR ARQ 168ARL Q 
     
ARQ/BSE 
 
ARQE175 ARQ VRQ ARR 
 
168ARL Q 
      
175 168consensus ARQ/ARQE VRQ ARR/ARL Q 
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